Skip to content

A bioequivalence study of ACT-541468 25 and 50mg tablet

Open-label, randomized, crossover phase 1 study to investigate bioequivalence between 2 x 25 mg tablet and 1 x 50 mg tablet of daridorexant in healthy adult male Japanese subjects

Status
Active, not recruiting
Phases
Phase 1
Study type
Interventional
Source
JPRN
Registry ID
JPRN-jRCT2071220009
Enrollment
64
Registered
2022-05-19
Start date
2022-05-17
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Insomnia

Interventions

Administration of ACT-541468 50mg once daily

Sponsors

Kawashima Takayuki
Lead Sponsor
Mochida Pharmaceutical Co., Ltd.
Collaborator

Eligibility

Sex/Gender
Male

Inclusion criteria

Inclusion criteria: (1) Signed informed consent for participation in the study prior to any study-mandated procedure. (2) Male Japanese aged 20 to 40 (inclusive) years at the time of informed consent (3) No relevant abnormalities on physical examination at screening and Pre-dose of Day 1 of Period 1. (4) BMI 18.5 to 25.0 kg/m2 at screening. (5) Blood pressure and pulse rate measured after 5 min in the supine position meet the following criteria at screening and Pre-dose of Day 1 of Period 1. Systolic blood pressure: 90 - 140 mmHg Diastolic blood pressure: 40 - 90 mmHg Pulse rate: 40-100 beats/min

Exclusion criteria

Exclusion criteria: (1) Known hypersensitivity to study drug or drugs of the same class, or any of the excipients of the drug formulation. (2) Known hypersensitivity or allergy to natural rubber or latex. (3) Previous relevant history of fainting, collapse, syncope, orthostatic hypotension, or vasovagal reactions. (4) Veins unsuitable for i.v. puncture on either arm (e.g., veins that are difficult to locate, access or puncture, veins with a tendency to rupture during or after puncture). (5) Treatment with another investigational drug within 4 months prior to screening or having participated in more than three investigational drug studies within 1 year prior to screening. (6) History or clinical evidence of alcoholism or drug abuse within the 3-year period prior to screening. (7) History or clinical evidence of any disease, and/or existence of any surgical or medical condition, which might interfere with the absorption, distribution, metabolism, or excretion of the study drug (appendectomy and herniotomy allowed; cholecystectomy not allowed).

Design outcomes

Primary

MeasureTime frame
Cmax, AUC0-t

Contacts

Public ContactTakayuki Kawashima

Idorsia Pharmaceuticals Japan Ltd

chiken.info-jp@idorsia.com+81-3-5204-5600

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026